Curriculum vitae, Maria Abbondanza Pantaleo,
MD
Date and place of birth: August 17, 1973, Scorrano (Le)
Italy
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES)
IRCSS Policlinico Sant'Orsola Malpighi, Medical Oncology Unit, Via Massarenti 9, 40138 Bologna
E-mail: maria.pantaleo@unibo.it
Telephone number: 0039 (0)51
6364078
Fax number: 0039 (0)51 6364037
Qualifications and Position:
University Position
- Associate Professor in Medical Oncology since 15/10/2014
- “Researcher in Medical Oncology” at University of
Bologna since 1 March 2006
- Medical Oncologist at Azienda Ospedaliero-Universitaria
Polilcinico Sant'Orosla Malpighi, SSD Oncologia Medica Biasco, 1
December 2006
PhD - “Experimental and clinical Oncology” of Modena and
Reggio Emilia University, 2005
Degree at School of Specialization in Medical Oncology at
Bologna University, November 09, 2002 cum summa laude
Degree in Medicine at University of Bologna, October 15, 1998
cum summa laude
Representative of Policlinico Sant'Orsola Malpighi in ERN EURACAN
Responsible of Oncology Research Projetcs of IRCCS Pol. Sant'Orsola
Director of Master in Clinical Study Coordinator
Professional Training:
Visiting the Internal Medicine Unit for 1 year at
Department of Clinical Medicine, Bologna University
Stage at Hematology Unit for 6 months to learn the high-dose
chemotherapy followed by autologous haematopoietic stem cell
transplantation, Bologna University
Stage at Oncology Unit for 1 year to learn the clinical and
therapy of solid tumors, Bologna University
Stage at Laboratory of gastrointestinal histopathology to learn
the biology of gastrointestinal carcinomas at Departement of
Clinical Medicine and Gastroenterology, Bologna University
Course in Cancer Genetics and Pediatric Oncology at Euoropean
School of Genetic Medicine, Genoa
Gastrointestinal Oncology Unit, Memorial Sloan-Kettering Cancer
Center, New York USA
Clinical Immunology Melanoma Unit, Memorial Sloan-Kettering
Cancer Center, New York USA
Breast Medical Oncology Unit, Memorial Sloan-Kettering Cancer
Center, New York USA
Grants:
· Grant for the
research project : “Biomolecular prognostic factors of colorectal
cancer” at Centro Interdipartimentale di ricerca sul Cancro
“Giorgio Prodi”. Funds: “Vanda Vanini” (January-May 2003)
· Grant for the
research project : “Novel approach for the screening of colon
cancer ” Funds: Ministero dell'Istruzione, dell'Università e della
ricerca, FIRB programme at University of Bologna (Aril-December
2003).
· Grant for the
research project : “Molecular and morphological characterization of
colorectal cancer and related clinical implications” at Centro
Interdipartimentale di ricerca sul Cancro “Giorgio Prodi” Funds:
Fondazione Cassa di Risparmio di Bologna (CARISBO (January 2004-
December 2005)
National and International
collaboration:
· Department of Experimental
Diagnostic Imaging, MD Anderson Cancer Center, University of Texas,
Houston USA
· Department of Nuclear
Medicine, Hadassah Hospital, Hebrew University Medical School,
Jerusalem, Israeli
· Department of Medicine,
Portland VA Medical Center and Oregon Health & Science
University Knight Cancer Institute, Oregon Health & Science
University, Portland, OR, USA
· Istituto Nazionale dei
Tumori, Milano
Membership:
· American
Society of Clinical Oncology (ASCO)
- American Association of Cancer Research (AACR)
- Associazione Italiana di Oncologia Medica (AIOM)
- European Socitiey of Medical Onoclogy (ESMO)
- Italian Sarcoma Group (ISG)
Main research fields:
Gastrointestinal stromal tumours (GIST) (www.giststudygroup.it)
Visceral Sarcoma (www.sarcomastudyroup.it)
Biomolecular prognostic factors of solid tumours and new
molecular targets for cancer therapy
Molecular Imaging in Medical Oncology
List of Clinical Trial in GCP :
Principal Investigator, Sub-investigator,
Co-Investigator
AXAGIST: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy
PROGENSARC: PROfilazione GENomica a scopo terapeutico nei SARComi e molecular tumor board (MTB): studio retrospettivo/prospettico in centri di riferimento
CGT9486-21-301: (PEAK) A Phase 3 Randomized, Open-Label, Multicenter Clinical Study Of Cgt9486+Sunitinib Vs Sunitinib In Subjects With Locally Advanced, Unresectable, Or Metastatic Gastrointestinal Stromal Tumors
EORTC-1553-SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Pfizer A6181036: "A treatment protocol for patients with
Gastro-intestinal stromal tumor who are ineligible for
participation in other SU011248 protocols and are refractory to or
intolerant of Imatinib Mesylate"
Pfizer A6181112: "A Phase IIIB, randomized, active
controlled open-label study of sunitinib malate (Sutent®) 37.5 mg
daily vs imatinib mesylate 800 mg daily in the treatment of
patients with Gastrointestinal Stromal Tumors (GIST) who have had
progressive disease while on 400 mg daily of imatinib"
Pfizer A6181078: "A treatment protocol for patients
continuing from a prior SU011248 protocol"
EORTC 62024: " Intermediate and high risk
localized,completely resected, gastrointestinal stromal tumors
(GIST) expressing KIT receptor : a controlled randomized trial on
adjuvant Imatinib mesylate (Glivec) versus no further therapy after
complete surgery"
CSTI571B2404 (GOLD reGISTry): "A global observational
registry collecting longitudinal data on patients with advanced
GIST"
CSTI571JDE74: "An open-label, multicenter, expanded
access study of imatinib mesylate in adult patients with GIST in
adjuvant setting after R0-resection"
CAMN107A2201: "A Randomized, Open-label, Multi-center
Study to Evaluate the Efficacy of Nilotinib Versus Best Supportive
Care With or Without a Tyrosine Kinase Inhibitor (Investigator's
Choice) in Adult Patients With Gastrointestinal Stromal Tumors
Resistant to Both Imatinib and Sunitinib"
CAMN107G2301: "A randomized, open-label, multi-center
phase III study to evaluate the efficacy and safety of nilotinib
vs. imatinib in adult patients with unresectable or metastatic
gastroinestinal stroma tumors (GIST)"
CAMN107DDE05: " An open-label, multi-center study to
evaluate the efficacy of nilotinib in adult patients with
gastrointestinal stromal tumors resistant to imatinib and
sunitinib"
EORTC 62063: “A phase III randomized study evaluating
surgery of residual disease in patients with metastatic
gastro-intestinal stromal tumor responding to Imatinib
mesylate”
Basket: “Open-label trial of Imatinib in patients with
Desmoid Tumor and Chondrosarcoma”
Novartis CAMN107A2409 “An Open Label,
Multi-center Nilotinib Roll-over Protocol for Patients Who Have
Completed a Previous Novartis-sponsored Nilotinib Study and Are
Judged by the Investigator to Benefit From Continued Nilotinib
Treatment”
Novartis CSTI571X2103: “A dose-finding phase Ib
multicenter study of imatinib in combination with the oral
phosphatidyl-inositol 3-kinase (PI3K) inhibitor BYL719 in patients
with gastrointestinal stromal tumor (GIST) who failed prior therapy
with imatinib and sunitinib”
Yondelis: “A non-interventional multicenter, prospective
study to evaluate treatment outcome as assessed in routine clinical
practice on patients with advanced soft tissue sarcoma treated with
trabectedin according to the Summary of Product Characteristics
(SmPC)”
ALDOXORUBIN-P3-STS-01 : Studio multicentrico,
randomizzato, in aperto, di Fase 3 per valutare l'efficacia e la
sicurezza di aldoxorubicina rispetto alla scelta dello
sperimentatore in soggetti con sarcomi dei tessuti molli
metastatici, localmente avanzati o non resecabili, recidivati o
refrattari dopo trattamento chemioterapico non adiuvante
Other CV Information
- Winner of Best Poster in Sarcoma section at European Society of
Medical Oncology (ESMO) Annual Meeting, Milan 2010 Title:1350P
CORRELATION OF MICRORNA PROFILE WITH KINASE GENOTYPE IN
GASTROINTESTINAL STROMAL TUMOURS (GISTS)
- Teacher at University of Bologna from 2006, Subject Medical
Oncology
- Project leader and coordinator of the multidisciplinary group:
"giststudygroup", University of Bologna
- Project leader and coordinator of the multidisciplinary group:
"sarcomastudygroup", University of Bologna
Pubblications: Author of more of 200 publications (see Publications section)
Conflict of Interests: Novartis Research Grants; Pfizer speaker fee; Lilly Oncology Speaker fee;Roche Advisory board; Deciphera Advosry Board; Blueprint Medicine Consultant.